The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease

Eur J Clin Pharmacol. 2009 Feb;65(2):157-61. doi: 10.1007/s00228-008-0578-3. Epub 2008 Oct 16.

Abstract

Objective: To investigate whether leptin receptor (LEPR) 223A>G polymorphism influences serum lipid levels and whether this polymorphism affects the effectiveness of simvastatin in Chinese patients with coronary heart disease (CHD).

Methods: A total of 312 patients with CHD were treated with simvastatin 20 mg/day. Fasting serum lipids were determined before and after 12 weeks of treatment.

Results: Patients with AA genotype had significantly higher total cholesterol (TC) levels and lower high-density lipoprotein cholesterol (HDL-C) levels than those with GG genotype (P < 0.05) before simvastatin treatment. In addition, the ability of simvastatin to increase HDL-C levels was significantly lower in patients with AA genotype than those with GG genotype (P < 0.05).

Conclusions: The 223A>G polymorphism of LEPR significantly modulates the HDL-C response to simvastatin in Chinese patients with CHD.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Alleles
  • Angiotensinogen / genetics*
  • Asian People
  • Coronary Disease / blood
  • Coronary Disease / drug therapy*
  • Coronary Disease / genetics
  • Coronary Disease / physiopathology
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Genotype
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Lipids / antagonists & inhibitors*
  • Lipids / blood
  • Lipids / chemistry
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Receptors, Leptin / genetics*
  • Simvastatin / pharmacology
  • Simvastatin / therapeutic use*
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipids
  • Receptors, Leptin
  • Angiotensinogen
  • Simvastatin